The Preventive Effectiveness of Rituximab in Pediatric Autoimmune and Inflammatory CNS Diseases Relapse: an Iranian Experience

Overview

Journal Iran J Child Neurol

Specialty Pediatrics

Date 2022 Oct 7

PMID 36204433

Authors

Mohammad Mahdi Nasehi

Mohammad Ghofrani

Aydin Tabrizi

Fatemeh Abdollah Gorji

Bakhtyar Khosravi

Affiliations

Soon will be listed here.

Abstract

Objectives: To determine the effectiveness of Rituximab (RTX) therapy as the first therapeutic choice for the long-term prevention of secondary relapse in children with AIND that had relapse after primary treatment with immunosuppressive agents other than RTX.

Materials & Methods: We conducted a single-center retrospective study of 9 consecutive pediatric patients (≤ 18 years old) registered on Autoimmune and Demyelinating Disorders Database (ADDD) of Mofid Children Hospital, from 2012 to 2016 and experienced relapse following therapeutic interventions with immunosuppressive agents other than RTX.

Result: A remarkable reduction of 94.13% (p=0.015) occurred in annualized relapse rate (ARR) as a clinical indicator of therapeutic efficacy comparing before and after initiating RTX therapy.

Conclusion: Rituximab is an effective drug in relapse prevention of AIND when administrated to patients for whom initial treatment with other immunosuppressive agents fail.POWER OF EVIDENCE: This study represents Class IV evidence that RTX therapy significantly reduces ARR in pediatric AIND including DDCNS.

References

Jacob A, Weinshenker B, Violich I, McLinskey N, Krupp L, Fox R . Treatment of neuromyelitis optica with rituximab: retrospective analysis of 25 patients. Arch Neurol. 2008; 65(11):1443-8. DOI: 10.1001/archneur.65.11.noc80069. View

Nosadini M, Alper G, Riney C, Benson L, Mohammad S, Ramanathan S . Rituximab monitoring and redosing in pediatric neuromyelitis optica spectrum disorder. Neurol Neuroimmunol Neuroinflamm. 2016; 3(1):e188. PMC: 4723136. DOI: 10.1212/NXI.0000000000000188. View

Lotze T, Northrop J, Hutton G, Ross B, Schiffman J, Hunter J . Spectrum of pediatric neuromyelitis optica. Pediatrics. 2008; 122(5):e1039-47. DOI: 10.1542/peds.2007-2758. View

Whittam D, Tallantyre E, Jolles S, Huda S, Moots R, Kim H . Rituximab in neurological disease: principles, evidence and practice. Pract Neurol. 2018; 19(1):5-20. DOI: 10.1136/practneurol-2018-001899. View

Longoni G, Banwell B, Filippi M, Yeh E . Rituximab as a first-line preventive treatment in pediatric NMOSDs: Preliminary results in 5 children. Neurol Neuroimmunol Neuroinflamm. 2014; 1(4):e46. PMC: 4268036. DOI: 10.1212/NXI.0000000000000046. View

Quartier P, Brethon B, Philippet P, Landman-Parker J, Le Deist F, Fischer A . Treatment of childhood autoimmune haemolytic anaemia with rituximab. Lancet. 2001; 358(9292):1511-3. DOI: 10.1016/s0140-6736(01)06573-4. View

Blaes F, Dharmalingam B . Childhood opsoclonus-myoclonus syndrome: diagnosis and treatment. Expert Rev Neurother. 2016; 16(6):641-8. DOI: 10.1080/14737175.2016.1176914. View

Chitnis T . Pediatric Central Nervous System Demyelinating Diseases. Continuum (Minneap Minn). 2019; 25(3):793-814. DOI: 10.1212/CON.0000000000000730. View

Pranzatelli M, Tate E, McGee N . Demographic, Clinical, and Immunologic Features of 389 Children with Opsoclonus-Myoclonus Syndrome: A Cross-sectional Study. Front Neurol. 2017; 8:468. PMC: 5604058. DOI: 10.3389/fneur.2017.00468. View

10.

Cree B, Lamb S, Morgan K, Chen A, Waubant E, Genain C . An open label study of the effects of rituximab in neuromyelitis optica. Neurology. 2005; 64(7):1270-2. DOI: 10.1212/01.WNL.0000159399.81861.D5. View

11.

Zarei S, Eggert J, Franqui-Dominguez L, Carl Y, Boria F, Stukova M . Comprehensive review of neuromyelitis optica and clinical characteristics of neuromyelitis optica patients in Puerto Rico. Surg Neurol Int. 2019; 9:242. PMC: 6293609. DOI: 10.4103/sni.sni_224_18. View

12.

Faurschou M, Hasselbalch H, Nielsen O . Sustained remission of platelet counts following monoclonal anti-CD20 antibody therapy in two cases of idiopathic autoimmune thrombocytopenia and neutropenia. Eur J Haematol. 2001; 66(6):408-11. DOI: 10.1034/j.1600-0609.2001.066006408.x. View

13.

Dalakas M . B cells in the pathophysiology of autoimmune neurological disorders: a credible therapeutic target. Pharmacol Ther. 2006; 112(1):57-70. DOI: 10.1016/j.pharmthera.2006.03.005. View

14.

Krumbholz M, Meinl E . B cells in MS and NMO: pathogenesis and therapy. Semin Immunopathol. 2014; 36(3):339-50. DOI: 10.1007/s00281-014-0424-x. View

15.

Pellkofer H, Krumbholz M, Berthele A, Hemmer B, Gerdes L, Havla J . Long-term follow-up of patients with neuromyelitis optica after repeated therapy with rituximab. Neurology. 2011; 76(15):1310-5. DOI: 10.1212/WNL.0b013e3182152881. View

16.

Borisow N, Mori M, Kuwabara S, Scheel M, Paul F . Diagnosis and Treatment of NMO Spectrum Disorder and MOG-Encephalomyelitis. Front Neurol. 2018; 9:888. PMC: 6206299. DOI: 10.3389/fneur.2018.00888. View

17.

Ringelstein M, Kleiter I, Ayzenberg I, Borisow N, Paul F, Ruprecht K . Visual evoked potentials in neuromyelitis optica and its spectrum disorders. Mult Scler. 2013; 20(5):617-20. DOI: 10.1177/1352458513503053. View

18.

Alexopoulos H, Biba A, Dalakas M . Anti-B-Cell Therapies in Autoimmune Neurological Diseases: Rationale and Efficacy Trials. Neurotherapeutics. 2015; 13(1):20-33. PMC: 4720683. DOI: 10.1007/s13311-015-0402-6. View

19.

Wingerchuk D, Banwell B, Bennett J, Cabre P, Carroll W, Chitnis T . International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology. 2015; 85(2):177-89. PMC: 4515040. DOI: 10.1212/WNL.0000000000001729. View

20.

Yamaguchi Y, Torisu H, Kira R, Ishizaki Y, Sakai Y, Sanefuji M . A nationwide survey of pediatric acquired demyelinating syndromes in Japan. Neurology. 2016; 87(19):2006-2015. PMC: 5109945. DOI: 10.1212/WNL.0000000000003318. View